Anticancer polypyrrole-polyethylenimine drug-free nanozyme for precise B-cell lymphoma therapy

Nguyen, Thi Thuy Dung; Chuang, Er‐Yuan; Chen, Yaping; Tseng, Po-Chun; Jhan, Ming-Kai; Lai, Chun-Yi; Wang, Yung-Ting; Hung, Yu-Ping; Changou, Chun A.; Lee, Chi-Ming; Chen, Chia-Ling; Lin, Chiou–Feng

doi:10.1016/j.biopha.2023.114397

Search citation statements

Order By: Relevance

Paper Sections

Select...

Methods1

Combination Therapy1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

2024

Publication Types

Select...

Article5

Book2

Relationship

Self Cite0

Independent7

Authors

Journals

Cited by 10 publications

(2 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Currently, nano-formulations formulated with drug-dye or polymeric-dye conjugates are considered reliable approaches for mimicking the biodistribution of nanomedicine in vivo. In this study, we employed polymeric-conjugated dyes (specifically, FITC-NHS ester) to create FITC-conjugated nano-formulation (PLTV–IO–MB PENPs), using methods previously reported [ 59 ].…”

Section: Methodsmentioning

confidence: 99%

Cold atmospheric plasma-enabled platelet vesicle incorporated iron oxide nano-propellers for thrombolysis

Jheng,

Chiang,

Kang

et al. 2023

Materials Today Bio

View full text Add to dashboard Cite

Section: Methodsmentioning

confidence: 99%

Cold atmospheric plasma-enabled platelet vesicle incorporated iron oxide nano-propellers for thrombolysis

Jheng,

Chiang,

Kang

et al. 2023

Materials Today Bio

View full text Add to dashboard Cite

“…Accurately triggering antitumor immune responses is a complex challenge. Nguyen et al 197 developed a novel nanocomposite polymer immunomodulator, the drug-free polypyrrole-polyethyleneimine nanozyme (PPY-PEI NZ). This nanozyme specifically responds to the B-cell lymphoma TME, aiming for precise cancer immunotherapy.…”

Section: Combination Therapymentioning

confidence: 99%

Nanozymes with biomimetically designed properties for cancer treatment

Xu,

Cui,

Guan

et al. 2024

Nanoscale

View full text Add to dashboard Cite

show abstract

Drug delivery methods for cancer immunotherapy

Pérez-Herrero

Lanier

Krishnan

et al. 2023

Drug Deliv. and Transl. Res.

View full text Add to dashboard Cite

Despite the fact that numerous immunotherapy-based drugs have been approved by the FDA for the treatment of primary and metastatic tumors, only a small proportion of the population can benefit from them because of primary and acquired resistances. Moreover, the translation of immunotherapy from the bench to the clinical practice is being challenging because of the short half-lives of the involved molecules, the difficulties to accomplish their delivery to the target sites, and some serious adverse effects that are being associated with these approaches. The emergence of drug delivery vehicles in the field of immunotherapy is helping to overcome these difficulties and limitations and this review describes how, providing some illustrative examples. Moreover, this article provides an exhaustive review of the studies that have been published to date on the particular case of hematological cancers. Graphical Abstract (Created with BioRender)

show abstract

Anticancer polypyrrole-polyethylenimine drug-free nanozyme for precise B-cell lymphoma therapy

Cited by 10 publications

References 47 publications

Cold atmospheric plasma-enabled platelet vesicle incorporated iron oxide nano-propellers for thrombolysis

Cold atmospheric plasma-enabled platelet vesicle incorporated iron oxide nano-propellers for thrombolysis

Nanozymes with biomimetically designed properties for cancer treatment

Drug delivery methods for cancer immunotherapy

Contact Info

Product

Resources

About